Stock listing

Dusseldorf:TCE2 Celldex Therapeutics, Inc. Aktie

German listing (Dusseldorf) of Celldex Therapeutics, Inc. · home listing NASDAQ:CLDX

Follow Celldex Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CLDX

$27.42 USD -0.13 (-0.5%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CLDX

Past year +9.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$26.64 – $28.43 USDNov 20, 2026
Volume
1.72M sharesNov 20, 2026
Market cap
$2.15B USDAt the close on Nov 20, 2026 · price × 78.55M shares outstanding
52-week range
$22.33 – $45.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$43.04M USDMedian day 924,313 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Celldex Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CLDX · Home$27.42 USD-0.13 (-0.5%)1,715,751$27.05$28.43$26.64$27.55Close on Nov 20, 2026
Frankfurt:TCE2€24.82 EUR+0.05 (+0.2%)—€24.82€24.82€24.82€24.77Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLDX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$27.42-0.13-0.5%$27.05$28.43$26.641,715,751
$27.55-0.49-1.7%$27.99$28.65$27.45679,608
$28.04-0.55-1.9%$28.77$29.31$27.50520,500
$28.59-0.24-0.8%$28.59$29.08$28.33572,353
$28.83+0.30+1.1%$28.41$28.95$28.00544,313
$28.53-1.62-5.4%$29.72$30.01$28.46867,083
$30.15-0.50-1.6%$30.86$31.10$30.14589,058
$30.65-0.59-1.9%$31.10$31.71$30.52820,579
$31.24+1.37+4.6%$30.52$31.66$29.421,858,087
$29.87+1.60+5.7%$27.85$30.15$27.82924,313
$28.27-1.66-5.5%$29.90$30.00$28.211,110,690
$29.93+0.22+0.7%$30.53$30.92$28.78749,135
$29.71+0.67+2.3%$29.36$29.95$28.67871,967
$29.04-1.06-3.5%$30.10$30.15$28.61956,132
$30.10+0.21+0.7%$29.70$30.12$29.20870,775
$29.89+0.23+0.8%$29.79$30.39$29.47916,683
$29.66-0.49-1.6%$29.63$30.02$28.92899,157
$30.15+0.65+2.2%$29.50$30.40$29.33746,577
$29.50+0.25+0.9%$29.90$29.90$28.99593,361
$29.25+0.28+1.0%$28.95$29.38$28.20879,733
$28.97-0.40-1.4%$29.08$29.73$28.49877,932
$29.37-0.92-3.0%$30.29$30.72$29.311,117,525
$30.29+0.62+2.1%$29.99$30.82$29.611,100,405
$29.67+2.14+7.8%$27.73$29.85$27.501,719,333
$27.53-1.40-4.8%$28.89$28.89$27.47997,900
$28.93+1.09+3.9%$28.05$28.95$27.651,181,700
$27.84-0.41-1.5%$28.49$28.73$27.681,044,300
$28.25-1.18-4.0%$29.28$29.28$27.921,897,900
$29.43-0.46-1.5%$29.61$30.03$28.99596,400
$29.89+0.59+2.0%$29.04$30.26$28.88992,700
$29.30-1.13-3.7%$30.07$30.10$28.633,950,400
$30.43-0.58-1.9%$30.62$31.35$30.111,746,900
$31.01-1.58-4.8%$32.68$32.68$30.851,768,200
$32.59+0.94+3.0%$31.83$32.88$31.501,257,900
$31.65-0.53-1.6%$32.26$32.54$30.982,404,700
$32.18-0.23-0.7%$32.26$32.55$31.701,442,300
$32.41+0.77+2.4%$31.71$32.76$31.452,502,000
$31.64+0.15+0.5%$31.49$31.79$31.002,029,400
$31.49+0.39+1.3%$31.06$32.15$30.381,824,100
$31.10-0.38-1.2%$31.48$31.71$30.652,023,800
$31.48+0.36+1.2%$31.48$31.66$30.592,297,500
$31.12-2.39-7.1%$33.54$33.59$30.414,235,600
$33.51-4.38-11.6%$36.60$38.39$30.3912,888,900
$37.89-0.35-0.9%$41.62$41.62$37.48549,500
$38.24-0.74-1.9%$38.87$38.87$37.542,081,900
$38.98+0.27+0.7%$39.47$40.66$38.921,278,900
$38.71+0.20+0.5%$38.59$39.21$38.251,001,400
$38.51-0.67-1.7%$39.00$39.19$37.74686,400
$39.18+2.28+6.2%$37.40$39.42$37.271,000,200
$36.90-1.20-3.1%$38.39$38.59$36.841,033,500
$38.10-0.68-1.8%$38.78$38.86$37.75949,000
$38.78-0.34-0.9%$38.95$40.04$38.67588,400
$39.12-0.56-1.4%$38.78$39.87$38.50834,300
$39.68+0.31+0.8%$38.96$39.81$38.90414,500
$39.37-0.11-0.3%$39.50$39.89$38.95418,000
$39.48+0.24+0.6%$39.43$40.55$39.01476,400
$39.24-0.39-1.0%$39.13$39.90$38.94542,500
$39.63+0.51+1.3%$38.86$39.84$38.74696,900
$39.12-1.34-3.3%$40.33$40.57$39.04424,900
$40.46-0.11-0.3%$40.44$41.00$40.02450,000
$40.57-0.65-1.6%$41.18$42.12$40.06540,700
$41.22+0.65+1.6%$41.02$41.92$40.63550,900
$40.57+0.19+0.5%$40.16$40.98$39.53416,900
$40.38+0.44+1.1%$40.38$41.24$40.12837,700
$39.94-1.76-4.2%$41.40$42.00$39.451,002,500

Splits

2 splits since 2008 · NASDAQ:CLDX · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-12Consolidation
Ticker
Dusseldorf:TCE2
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Celldex Therapeutics, Inc. news

Celldex Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 150 in all · newest Nov 19, 2026 · oldest 2019
Calls
5 calls with a replay · 5 with a transcript · latest Jun 12, 2025
Decks
14 decks · latest Sep 22, 2026

Where Celldex Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CLDX · Home listingNASDAQUnited StatesUSD
gettex:TCE2gettexGermanyEUR
Lang & Schwarz:A2PEABLang & SchwarzGermanyEUR
LS Exchange:A2PEABLS ExchangeGermanyEUR
Tradegate:TCE2TradegateGermanyEUR
BOATS:CLDXBOATSUnited StatesUSD
BX Swiss:TCE1BX SwissSwitzerlandCHF
Dusseldorf:TCE2 · This pageDusseldorfGermanyEUR
Frankfurt:TCE2FrankfurtGermanyEUR
Munich:TCE2MunichGermanyEUR
Stuttgart:TCE2StuttgartGermanyEUR

Valuation

Price/book 3.3× against a median of 6.9×: 4th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.50B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
3.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.07

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Celldex Therapeutics, Inc. · NASDAQ:CLDXUS$2.15BUS$1.50Bn/an/an/a3.3×n/a0.0×1.07
SK bioscience Co.,Ltd. · KRX:302440US$2.26BUS$2.03Bn/a4.1×n/a1.7×−12.8%0.3×n/a
Arcus Biosciences, Inc. · NYSE:RCUSUS$2.25BUS$1.72Bn/a17.2×n/a6.3×−453.0%0.3×1.37
NewAmsterdam Pharma Company N.V. · NASDAQ:NAMSUS$2.20BUS$1.57Bn/a60.6×n/a3.5×−789.9%0.0×1.41
Lakefront Biotherapeutics · EURONEXT:LKFTUS$2.20B−US$260.8M3.4×−0.2×n/a0.6×60.2%0.0×n/a
Pharvaris N.V. · NASDAQ:PHVSUS$2.20BUS$1.89Bn/an/an/a7.5×n/a0.0×0.76
BioArctic AB Class B · OMXSTO:BIOA_BUS$2.19BUS$2.00B212×20.4×90.0×11.1×10.5%0.0×n/a
Beam Therapeutics Inc. · NASDAQ:BEAMUS$2.16BUS$1.22Bn/a8.3×n/a2.3×−73.9%0.1×1.90
Palvella Therapeutics, Inc. · NASDAQ:PVLAUS$2.09BUS$1.85Bn/an/an/a10.6×n/a0.0×1.50
Regencell Bioscience Holdings Limited · NASDAQ:RGCUS$2.07BUS$2.06Bn/an/an/a155×n/a0.0×1.57
Hanall Biopharma Co., Ltd. · KRX:009420US$2.05BUS$2.03Bn/a16.7×335×16.9×−15.3%0.1×n/a
Median of the othersUS$2.19BUS$1.87B108×16.7×212×6.9×−15.3%0.0×1.46

Forecasts

12 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
64.00 USD · Analysts' mean
EPS, year to Dec 2026
-4.05 · 9 analysts
Revenue, year to Dec 2026
1.43M · 11 analysts

Team and board

Officers

OfficerRole
Anthony S. MarucciFounder, President, Chief Executive Officer and Director
Denice TorresChief Executive Officer; The Ignited Company
Garry NeilChief Executive Officer; Chair of the Board, Avalo Therapeutics
Sam MartinSenior Vice President and Chief Financial Officer
Cheryl L. CohenPresident, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
Freddy A. JimenezSenior Vice President and General Counsel
Elizabeth HigginsExecutive Director, Investor Relations & Corporate Communications
Diane C. YoungSenior Vice President and Chief Medical Officer
Elizabeth CrowleySenior Vice President, Chief Product Development Officer
Margo Heath-ChiozziSenior Vice President, Regulatory Affairs
Ronald A. PepinSenior Vice President and Chief Business Officer
Sarah CavanaughSenior Vice President, Corporate Affairs and Administration
Teri LawverSenior Vice President, Chief Commercial Officer
Tibor KelerFounder, Executive Vice President and Chief Scientific Officer

Board

DirectorRole
Garry NeilChief Executive Officer; Chair of the Board, Avalo Therapeutics
Anthony S. MarucciFounder, President, Chief Executive Officer and Director
Elizabeth HigginsExecutive Director, Investor Relations & Corporate Communications

Events

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+5.7%
Q2 2026Aug 6, 2026 · After close+0.4%
Q1 2026May 7, 2026 · After close+1.9%
Q4 2025Mar 2, 2026−3.8%
Q3 2025Nov 10, 2025 · After close+7.5%
Q2 2025Aug 7, 2025 · After close−2.6%
Q1 2025May 8, 2025 · After close−6.1%
Q4 2024Feb 24, 2025 · Before open−5.0%
Q3 2024Nov 6, 2024 · After close−4.2%
Q2 2024Aug 8, 2024 · After close+0.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · After close+1.3%
Q4 2023Feb 26, 2024 · Before open+27.8%
Q3 2023Nov 2, 2023 · After close+8.2%
Q2 2023Aug 8, 2023 · After close−5.8%
Q1 2023May 4, 2023 · After close+5.7%
Q4 2022Feb 28, 2023 · After close+8.5%
Q3 2022Nov 9, 2022 · After close+16.0%
Q2 2022Aug 8, 2022 · After close−5.8%
Q1 2022May 5, 2022 · After close−5.0%
Q4 2021Feb 28, 2022 · After close+5.6%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical21 slidesSep 22, 2026
Technical Presentation (June 2026)Technical13 slidesJune 2026
Technical Presentation (June 2026)Technical10 slidesJune 2026
EAACI Congress 2025Conference14 slidesJun 13, 2025
European Academy of Dermatology and Venereology (EADV 2024)Conference16 slides2024
FY2021 Earnings PresentationEarnings25 slidesFebruary 2022
FY2014 Earnings PresentationEarnings19 slidesFeb 24, 2015
Technical Presentation (November 2013)Technical31 slidesNov 25, 2013
Technical Presentation (November 2013)Technical20 slidesNovember 2013
FY2012 Earnings PresentationEarnings12 slidesMar 7, 2013
All 14 decks
DeckKindSlidesDate
Investor Presentation (January 2013)Investor deck27 slidesJan 7, 2013
Technical Presentation (May 2012)Technical16 slidesMay 24, 2012
Merger or Acquisition (June 2009)Merger or acquisition17 slidesJun 9, 2009
Technical Presentation (June 2009)Technical23 slidesJun 2, 2009

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.54M7.02M6.88M2.36M4.65M7.42M3.57M9.54M12.7M6.79M
Cost of revenue200.0K200.0K300.0K100.0K100.0K200.0K100.0K700.0K700.0K1.60M
Gross profit1.34M6.82M6.58M2.26M4.55M7.22M3.47M8.84M12.0M5.19M
Research and development245.1M163.6M118.0M82.3M53.3M42.5M42.7M66.4M96.2M102.7M
Operating income-287.4M-195.1M-154.5M-115.2M-71.2M-63.4M-55.0M-156.4M-121.5M-132.9M
Depreciation and amortization3.38M3.18M3.01M2.90M3.07M3.93M4.86M3.58M4.41M3.10M
EBITDA-284.0M-191.9M-151.5M-112.3M-68.2M-59.4M-50.2M-152.9M-117.1M-129.8M
Income before tax-258.8M-157.9M-141.4M-112.3M-70.7M-60.9M-50.9M-151.9M-117.3M-128.5M
Income tax000-227.0K-1.17M-765.0K-24.3M
Net income-258.8M-157.9M-141.4M-112.3M-70.5M-59.8M-50.9M-151.2M-93.0M-128.5M
Earnings per share, basic-3.90-2.45-2.92-2.40-1.64-2.02-3.51-14.48-10.86-18.99
Earnings per share, diluted-3.90-2.45-2.92-2.40-1.64-2.02-3.51-14.48-10.86-18.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents28.9M28.4M34.8M29.4M39.1M43.8M11.2M24.3M40.3M42.5M
Short-term investments489.7M696.9M388.8M275.5M369.1M150.6M53.2M69.7M99.1M147.3M
Current assets534.7M747.2M431.7M317.7M410.8M197.8M66.7M99.1M144.8M195.6M
Property, plant and equipment5.33M4.35M4.06M3.75M3.55M3.81M4.03M6.11M10.4M13.2M
Goodwill91.0M91.0M
Total assets583.0M792.3M465.6M352.7M444.7M235.8M122.9M155.8M315.6M383.4M
Accounts payable1.18M3.27M3.49M3.34M1.23M1.05M1.17M1.07M1.72M1.74M
Current liabilities51.0M39.5M31.1M18.6M16.5M14.2M11.6M12.6M27.7M35.2M
Total liabilities55.8M45.3M36.5M26.5M25.2M26.5M28.9M31.7M79.3M117.9M
Shareholders' equity527.2M747.0M429.2M326.2M419.5M209.4M94.0M124.1M236.4M265.4M
Shares outstanding66.5M66.4M55.9M47.2M46.7M39.6M17.0M12.0M9.23M120.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-210.9M-157.8M-107.3M-103.7M-60.9M-40.4M-46.4M-75.2M-99.9M-113.0M
Capital spending-2.71M-1.92M-1.82M-1.83M-1.25M-1.55M-731.0K-813.0K-1.79M-2.75M
Free cash flow-213.7M-159.7M-109.1M-105.6M-62.2M-42.0M-47.1M-76.0M-101.7M-115.8M
Cash from investing209.1M-290.1M-105.8M89.9M-216.2M-98.2M17.1M29.8M46.5M68.9M
Cash from financing2.39M441.4M218.5M4.08M272.4M171.2M16.3M29.4M51.3M14.5M
Change in cash515.0K-6.46M5.38M-9.71M-4.69M32.6M-13.1M-16.0M-2.17M-29.6M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
S-3ASR · Registration statementNov 5, 2026Offer documentSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2026Big-stake noticeSEC
8-K · Current reportSep 22, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJul 15, 2026Management or board changeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 26, 2026Offer documentSEC
8-K · Current reportJun 26, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
424B5 · ProspectusApr 2, 2026Offer documentSEC
8-K · Current reportApr 2, 2026Material contractSEC
424B5 · ProspectusApr 1, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 10, 2026Big-stake noticeSEC
10-K · Annual reportFeb 25, 2026Annual reportSEC
8-K · Current reportFeb 25, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 12, 2025Insider tradeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
8-K · Current reportAug 19, 2025Current reportSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 10, 2025Big-stake noticeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJun 6, 2025Offer documentSEC
3 · Initial statement of ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 21, 2025Annual reportSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 10, 2025Big-stake noticeSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
144 · Notice of proposed saleJun 14, 2024Other filingsSEC
144 · Notice of proposed saleJun 14, 2024Other filingsSEC
S-8 · Registration statement for employee plansJun 14, 2024Offer documentSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
144 · Notice of proposed saleJun 7, 2024Other filingsSEC
144 · Notice of proposed saleJun 7, 2024Other filingsSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
144 · Notice of proposed saleJun 3, 2024Other filingsSEC
144 · Notice of proposed saleJun 3, 2024Other filingsSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
144 · Notice of proposed saleMay 30, 2024Other filingsSEC
144 · Notice of proposed saleMay 30, 2024Other filingsSEC
144 · Notice of proposed saleMay 30, 2024Other filingsSEC
144 · Notice of proposed saleMay 30, 2024Other filingsSEC
10-Q · Quarterly reportMay 6, 2024Quarterly reportSEC
8-K · Current reportMay 6, 2024ResultsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
8-K · Current reportMar 1, 2024Material contractSEC
424B5 · ProspectusMar 1, 2024Offer documentSEC
424B5 · ProspectusFeb 28, 2024Offer documentSEC
424B5 · ProspectusFeb 26, 2024Offer documentSEC
10-K · Annual reportFeb 26, 2024Annual reportSEC
8-K · Current reportFeb 26, 2024ResultsSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2024Big-stake noticeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 20, 2023Big-stake noticeSEC
8-K · Current reportNov 8, 2023Material contractSEC
424B5 · ProspectusNov 8, 2023Offer documentSEC
424B5 · ProspectusNov 7, 2023Offer documentSEC
8-K · Current reportNov 6, 2023Current reportSEC
S-3ASR · Registration statementNov 3, 2023Offer documentSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
S-8 · Registration statement for employee plansJun 21, 2023Offer documentSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Celldex Therapeutics, Inc.’s releases · as of Oct 28, 2026

Common shares
78,545,051
Fully diluted
78,545,051

Fully diluted

LineSharesAs of
Common shares78,545,051Oct 28, 2026

Share count over time

CountShares
Oct 28, 202678,545,051

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Wellington10.7MUS$346MSep 30, 2026
Fidelity8.64MUS$280MSep 30, 2026
BlackRock6.95MUS$225MSep 30, 2026
Kynam Capital Management, LP5.07MUS$164MSep 30, 2026
Vanguard5.04MUS$163MSep 30, 2026
T. Rowe Price4.39MUS$142MSep 30, 2026
State Street3.48MUS$113MSep 30, 2026
Baker Bros. Advisors LP2.56MUS$83.1MSep 30, 2026
Deep Track Capital, LP2.13MUS$68.9MSep 30, 2026
Geode Capital2.05MUS$66.4MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Eventide Asset Management, LLC1.9MUS$61.5MSep 30, 2026
Goldman Sachs1.62MUS$52.5MSep 30, 2026
Driehaus Capital Management LLC1.4MUS$45.3MSep 30, 2026
Fisher Asset Management, LLC1.25MUS$40.4MSep 30, 2026
Eversept Partners, LP1.17MUS$38.1MSep 30, 2026
Affinity Asset Advisors, LLC1.16MUS$37.6MSep 30, 2026
Dimensional1.15MUS$37.2MSep 30, 2026
Elmind Capital, LP1.11MUS$36MSep 30, 2026
UBS1.07MUS$34.8MSep 30, 2026
Federated Hermes, Inc.1.05MUS$34MSep 30, 2026
American Century1.05MUS$33.9MSep 30, 2026
Commodore Capital LP1MUS$32.4MSep 30, 2026
Novo Holdings A/S950KUS$30.8MSep 30, 2026
Frazier Life Sciences Management, L.P.900KUS$29.2MSep 30, 2026
Two Sigma882KUS$28.6MSep 30, 2026
Bank of America871KUS$28.2MSep 30, 2026
ADAR1 Capital Management, LLC799KUS$25.9MSep 30, 2026
Trails Edge Capital Partners, LP765KUS$24.8MSep 30, 2026
Northern Trust715KUS$23.2MSep 30, 2026
Woodline Partners LP701KUS$22.7MSep 30, 2026
Schwab697KUS$22.6MSep 30, 2026
Algert Global LLC692KUS$22.4MSep 30, 2026
Rock Springs Capital Management LP653KUS$21.2MSep 30, 2026
Panagora Asset Management Inc626KUS$20.3MSep 30, 2026
Morgan Stanley596KUS$19.3MSep 30, 2026
Pictet Asset Management Holding SA548KUS$17.7MSep 30, 2026
Ikarian Capital, LLC519KUS$16.8MSep 30, 2026
Candriam S.C.A.518KUS$16.9MSep 30, 2026
Orbimed Advisors LLC505KUS$16.4MSep 30, 2026
Silverarc Capital Management, LLC488KUS$15.8MSep 30, 2026
Qube Research & Technologies Ltd451KUS$14.6MSep 30, 2026
Assenagon Asset Management S.A.445KUS$14.4MSep 30, 2026
Nuveen426KUS$13.8MSep 30, 2026
5AM Venture Management, LLC422KUS$13.7MSep 30, 2026
TSP Capital Management Group, LLC371KUS$12MSep 30, 2026
Kennedy Capital Management LLC362KUS$11.7MSep 30, 2026
Palo Alto Investors LP343KUS$11.1MSep 30, 2026
Millennium337KUS$10.9MSep 30, 2026
Jump Financial, LLC325KUS$10.5MSep 30, 2026
Redmile Group, LLC322KUS$10.4MSep 30, 2026

This page holds 50 of 241 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Health Care Fund3.78MUS$144MJul 31, 2026
Vanguard Total Stock Market Index Fund2.49MUS$92.6MJun 30, 2026
iShares Russell 2000 ETF2.03MUS$75.6MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.03MUS$75.4MJun 30, 2026
Vanguard Explorer Fund1.45MUS$55.1MJul 31, 2026
T. Rowe Price New Horizons Fund, Inc.1.25MUS$46.7MJun 30, 2026
Eventide Healthcare & Life Sciences Fund1.04MUS$38.6MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund971KUS$36.1MJun 30, 2026
Vanguard Extended Market Index Fund898KUS$33.4MJun 30, 2026
Fidelity Small Cap Index Fund855KUS$32.5MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Small Cap Growth Fund793KUS$30.2MJul 31, 2026
iShares Russell 2000 Growth ETF579KUS$21.6MJun 30, 2026
Federated Hermes Kaufmann Fund530KUS$20.2MJul 31, 2026
Fidelity Advisor Biotechnology Fund512KUS$19.5MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund512KUS$16.1MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.495KUS$18.4MJun 30, 2026
Fidelity Small Cap Growth Fund474KUS$18MJul 31, 2026
Fidelity Small Cap Discovery Fund434KUS$16.5MJul 31, 2026
Fidelity Extended Market Index Fund397KUS$12.5MMay 31, 2026
Nuveen Quant Small Cap Equity Fund394KUS$15MJul 31, 2026
Vanguard Russell 2000 Index Fund389KUS$12.2MMay 31, 2026
Fidelity Series Small Cap Discovery Fund377KUS$14.3MJul 31, 2026
Schwab U.S. Small-Cap ETF369KUS$11.6MMay 31, 2026
Federated Hermes Kaufmann Small Cap Fund325KUS$12.4MJul 31, 2026
Fidelity Small Cap Growth K6 Fund238KUS$9.05MJul 31, 2026
U.S. Small Cap Portfolio236KUS$8.97MJul 31, 2026
Driehaus Small Cap Growth Fund209KUS$7.79MJun 30, 2026
Dimensional U.S. Small Cap ETF203KUS$7.71MJul 31, 2026
Vanguard Health Care Index Fund201KUS$6.33MMay 31, 2026
Schwab Small-Cap Index Fund190KUS$7.23MJul 31, 2026
BlackRock Advantage Small Cap Core Fund179KUS$5.62MMay 29, 2026
U.S. Micro Cap Portfolio170KUS$6.48MJul 31, 2026
Small Cap Growth Stock Portfolio158KUS$5.88MJun 30, 2026
North Square Dynamic Small Cap Fund154KUS$4.83MMay 31, 2026
Fidelity Series Small Cap Core Fund150KUS$5.72MJul 31, 2026
The Hartford Small Company Fund150KUS$5.69MJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund149KUS$5.68MJul 31, 2026
Master Small Cap Index Series145KUS$5.39MJun 30, 2026
Fidelity Total Market Index Fund145KUS$4.54MMay 31, 2026
T. Rowe Price Small-Mid Cap ETF140KUS$5.21MJun 30, 2026
iShares Russell 2000 Value ETF138KUS$5.15MJun 30, 2026
Fidelity Series Total Market Index Fund117KUS$3.68MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF116KUS$4.33MJun 30, 2026
Hartford Small Cap Growth Hls Fund114KUS$4.25MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio108KUS$4.02MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund106KUS$3.95MJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund106KUS$4.03MJul 31, 2026
The Hartford Healthcare Fund105KUS$3.99MJul 31, 2026
Nuveen Small Cap Blend Index Fund103KUS$3.94MJul 31, 2026
Vanguard Strategic Equity Fund100KUS$3.74MJun 30, 2026

This page holds 50 of 246 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Wellington Management Group LLP13.90%11MSep 30, 2026Schedule 13G
FMR LLC10.70%8.41MSep 30, 2026Schedule 13G
BlackRock, Inc.7.30%4.82MMar 31, 2025Schedule 13G
Kynam Capital Management, LP6.78%0Jun 30, 2026Schedule 13G
T. Rowe Price Associates Inc6.00%4.69MJun 30, 2026Schedule 13G
Vanguard Capital Management LLC5.17%3.45MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Denice Torres
Other companies: Seaport Therapeutics, Inc. (Board Member · Since at least Apr 30, 2026); Glaukos Corporation (Director · Since at least Mar 1, 2021); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past); Surface Oncology Inc (Director · Jul 6, 2021 – Jun 8, 2022 · Past); Karuna Therapeutics Inc (Director · Dec 22, 2020 – Mar 18, 2024 · Past); Bluebird bio Inc (Director · Aug 10, 2020 – Nov 11, 2021 · Past)
Chief Executive Officer; The Ignited Company · Since at least Jun 5, 2025
Timothy M Shannon
Other companies: Rallybio Corporation (Director · Jul 28, 2021 – Jan 3, 2022 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – Jun 7, 2023 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 13, 2019 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Nov 29, 2016 · Past); Curagen Corp (Former President and CEO, Director · May 25, 2007 – Oct 1, 2009 · Past)
Director · Oct 1, 2009 – Jun 4, 2014 · Past
Richard A. van den Broek
Other companies: Corvus Pharmaceuticals, Inc. (Board Member · Since at least Apr 8, 2025); Pulse Biosciences, Inc (Director · Since at least Aug 6, 2020); PhaseBio Pharmaceuticals Inc (Director · Feb 27, 2019 – May 19, 2023 · Past); Pharmacyclics Inc (Director · Oct 3, 2011 – May 26, 2015 · Past)
Director · Dec 17, 2014 – Jun 8, 2016 · Past
Rita Jain
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); SAB Biotherapeutics, Inc. (Director · Since at least Jan 5, 2026); Avalo Therapeutics, Inc. (Director · Since at least Jun 17, 2025); AnaptysBio, Inc. (Director · Since at least Jan 3, 2024)
Director · Since at least Jun 13, 2024
Herbert J. Conrad
Other companies: Matinas BioPharma Holdings, Inc. (Director · Mar 1, 2017 – Nov 1, 2023 · Past); Arbutus Biopharma Corporation (Director · Mar 4, 2015 – Jun 19, 2018 · Past); Savient Pharmaceuticals Inc (Director · Dec 30, 2005 – Jun 8, 2010 · Past)
Director · Since at least Mar 7, 2008
Keith L Brownlie
Other companies: Cancer Genetics Inc (Director · Jul 24, 2013 – May 22, 2014 · Past); Phio Pharmaceuticals Corp. (Director · Mar 1, 2013 – Feb 13, 2019 · Past); Soligenix, Inc. (Director · Jun 21, 2012 – Sep 27, 2018 · Past)
Director · Since at least Jun 15, 2017
George O. Elston
Other companies: EyePoint, Inc. (Executive Vice President, Chief Financial Officer · Since at least Nov 14, 2019); Juniper Pharmaceuticals Inc (Chief Financial Officer · Oct 1, 2014 – Aug 31, 2016 · Past)
Director · Jun 20, 2012 – Jun 8, 2016 · Past
Gerald PhD McMahon
Other companies: Harpoon Therapeutics Inc (President and CEO, Director · Feb 7, 2019 – Jan 28, 2021 · Past); Oncotelic Therapeutics Inc (Director · Sep 2, 2011 – Jun 1, 2016 · Past)
Director · Dec 14, 2016 – Dec 3, 2018 · Past
Teri Lawver
Other companies: Altimmune, Inc. (Director · Since at least Feb 24, 2025); DexCom, Inc. (EVP Chief Commercial Officer · Jan 9, 2023 – Mar 12, 2024 · Past)
Senior Vice President, Chief Commercial Officer · Since at least Nov 10, 2025
Cheryl L. Cohen
Other companies: ImmunityBio, Inc. (Director · Since at least Jun 11, 2024)
Director · Since at least Jun 13, 2024
All 31 people
PersonSeat
Diane C. Young
Other companies: Oncternal Therapeutics Inc (VP, Chief Medical Officer · Jul 13, 2015 – Jul 13, 2018 · Past)
Senior Vice President and Chief Medical Officer · Since at least Jul 8, 2019
Garry A. Neil
Other companies: Avalo Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Aug 13, 2024)
Director · Since at least Jun 13, 2024
James J Marino
Other companies: Traws Pharma, Inc. (Director · Nov 24, 2020 – Aug 10, 2023 · Past)
Director · Since at least Jun 17, 2021
Larry Ellberger
Other companies: Omrix Biopharmaceuticals Inc (Director · Aug 7, 2006 – Sep 4, 2008 · Past)
Director · May 25, 2006 – Jun 13, 2018 · Past
Rajesh R Parekh
Other companies: Aura Biosciences, Inc. (Director · Oct 28, 2021 – Jun 7, 2023 · Past)
Director · Dec 23, 2009 – Sep 22, 2010 · Past
Thomas Andrew Davis
Other companies: GenVec Inc (Chief Medical Officer · Nov 22, 2005 – Jan 18, 2006 · Past)
Executive VP & CMO · Mar 7, 2008 – Jun 15, 2017 · Past
Anthony S. MarucciFounder, President, Chief Executive Officer and Director · Since at least Jan 6, 2009
Elizabeth CrowleySenior Vice President, Chief Product Development Officer · Since at least May 30, 2024
Elizabeth HigginsExecutive Director, Investor Relations & Corporate Communications · Since at least Sep 22, 2026
Freddy A. JimenezSenior Vice President and General Counsel · Since at least Jan 1, 2021
Harry H. PennerSince at least Nov 4, 2026
Harry Penner JrDirector · Since at least May 25, 2006
J Barrie WardDirector · May 25, 2006 – May 25, 2006 · Past
Margo Heath-ChiozziSenior Vice President, Regulatory Affairs · Since at least Oct 3, 2017
Richard M WrightSR. VP & CCO · Jul 1, 2015 – Jun 13, 2024 · Past
Ronald A. PepinSenior Vice President and Chief Business Officer · Since at least Nov 4, 2026
Sam MartinSenior Vice President and Chief Financial Officer · Since at least Jul 15, 2026
Samuel Bates MartinSVP AND CFO · Since at least Jul 1, 2017
Sarah CavanaughSenior Vice President, Corporate Affairs and Administration · Since at least Sep 22, 2026
Theresa LaValleeSVP, Reg.& Precision Medicine · Nov 29, 2016 – Dec 14, 2016 · Past
Tibor KelerEXECUTIVE VP & CSO · Since at least Jun 13, 2024

Open People

Log in to ask 6ix AI your own questions about Celldex Therapeutics, Inc.